SON-1010
Sonnet BioTherapeutics
['sonnet']
we re very pleased to share the latest phase 1 clinical data from our lead candidate, son-1010, which not only shows favorable safety and tolerability, but also shows early signs of activity against tumors in cancer patients. #cancer #oncology #immunooncology #aacr23 
Experts in immune-oncology therapies developing proprietary FHAB™ (Fully Human Albumin Binding) technology. (NASDAQ: $SONN)